UK Center for Clinical and Translational Science

Cabozantinib and Pembrolizumab in Metastatic Pancreas

This study aims to evaluate cabozantinib and pembrolizumab for the treatment of metastatic pancreatic adenocarcinoma.

Diagnosis of pancreatic ductal adenocarcinoma - Evidence of progression or intolerance to previous standard of care pancreatic cancer systemic or locoregional therapies - Patients must have adequate organ function

Chemotherapy or other locoregional anti-tumoral therapies performed within 28 days of study treatment initiation - Received palliative radiation therapy within 2 weeks or any other radiation therapy within 4 weeks of start of study intervention - Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to allocation - Has a diagnosis of immunodeficiency (autoimmune disease) or is receiving chronic systemic steroid therapy - Clinically significant cardiovascular disease - Uncontrolled hypertension - Inability to swallow tablets

Arm	Description	Assigned Intervention
Experimental Cabozantinib and pembrolizumab		Drug: Cabozantinib Cabozantinib (XL184) is a potent inhibitor of multiple receptor tyrosine kinases (RTKs) known to play important roles in tumor cell proliferation and/or tumor neovascularization. Drug: Pembrolizumab Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD-1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).